About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Treatment Approach in Stage III NSCLC
Treatment Approach in Stage III NSCLC
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
New Options in Stage III NSCLC
By
Federico Cappuzzo
18 Videos
220 views
November 10, 2022
0 Comments
Login to view comments.
Click here to Login
Treatment Approach in Stage III NSCLC
09:40
John Conibear
PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC
10:51
Winship Cancer Institute - Emory University
Optimising Chemoradiation to Reduce Pneumonitis Risk in Patients Wit…
Feat.
N. McCall
10:47
Giulia Pasello
The Multidisciplinary Approach in Stage III NSCLC Over 10 Years: Fro…
12:40
Yale Cancer Center
Consolidation IO Following CRT in Stage III NSCLC
Feat.
H. Park
15:01
OncoAlert
Radiation Oncology 2022: Advances in NSCLC
Feat.
H. Willers,
A. Wisdom
09:13
Federico Cappuzzo
New Options in Stage III NSCLC
12:41
Lung Cancer Europe (LuCE)
Unresectable Stage III NSCLC: Key Findings
Feat.
J. Naidoo
14:23
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage
Updates on the Use of Consolidation IO in NSCLC Based on Biomarker S…
Feat.
E. Vokes
41:16
Total Health
2023 Case-Based Clinical Updates in Lung Cancer
Feat.
N. Seetharamu
22:46
2023 Texas Lung Cancer Conference Coverage
When Is PD(L)1 Monotherapy for NSCLC Enough?
Feat.
S. Gadgeel
23:36
CHEST 2022 Coverage
Immune Checkpoint Inhibitor Pneumonitis in Lung Cancer
Feat.
J. Possick
19:41
Balazs Halmos
How I Manage Immune Adverse Events in Solid Tumors
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage
Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …
Feat.
E. Rodriguez
37:21
Moffitt Cancer Center
Managing Immunotherapy-Related Adverse Events
Feat.
K. Hendrix,
S. Logan
17:57
2023 Texas Lung Cancer Conference Coverage
Advantages of Chemoimmunotherapy for NSCLC
Feat.
M. Johnson
07:58
Janeesh Sekkath Veedu
Survival Outcomes of Surgery-Based Treatment or Definitive CRT With …
20:34
2023 Texas Lung Cancer Conference Coverage
Current Role of Adjuvant IO in NSCLC
Feat.
J. Donington
16:36
Fox Chase Cancer Center
Adjuvant Therapy for Resectable NSCLC: State of the Art
Feat.
M. Edelman
08:55
Insights from 2023 ASCO® Annual Meeting
Surgical Aspects in the Treatment of Locally Advanced NSCLC
Feat.
G. Veronesi
08:05
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ARC-7: Randomized Phase 2 Study of Domvan…
Feat.
M. Johnson
